(HRTX) Heron Therapeuti - Overview
Stock: Chemotherapy-Nausea Drug, Post-Surgery-Nausea Drug, Extended-Release-Gel
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 92.7% |
| Relative Tail Risk | -19.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.20 |
| Alpha | -46.48 |
| Character TTM | |
|---|---|
| Beta | 0.908 |
| Beta Downside | 0.575 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.25% |
| CAGR/Max DD | -0.27 |
Description: HRTX Heron Therapeuti December 31, 2025
Heron Therapeutics (NASDAQ:HRTX) is a commercial-stage biotech that leverages its proprietary Biochronomer delivery platform to extend the exposure of short-acting drugs, enabling single-dose regimens that last from days to weeks. Its current marketed products include SUSTOL (granisetron) for chemotherapy-induced nausea and vomiting (CINV) in moderate-risk regimens and CINVANTI (IV aprepitant) for high- and moderate-risk CINV, while its pipeline features ZYNRELEF (bupivacaine/meloxicam) for postoperative pain and APONVIE (IV NK-1 antagonist) for postoperative nausea and vomiting.
Key quantitative signals as of Q3 2024: market capitalization ≈ $210 M; cash and equivalents $95 M, giving roughly 12-month runway at current burn (~$8 M / quarter). The CINV market is projected to grow > 6% CAGR through 2028, driven by increasing oncology therapy utilization and stronger reimbursement for antiemetic combos. Heron’s recent FDA approval of CINVANTI’s expanded indication (2023) lifted its revenue run-rate to $12 M (FY 2023) and the company expects ZYNRELEF to add $15-$20 M in annual sales if it secures a 2025 launch.
For a deeper quantitative view, you might explore ValueRay’s analyst dashboard.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -13.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.13 > 0.02 and ΔFCF/TA -8.16 > 1.0 |
| NWC/Revenue: 90.07% < 20% (prev 79.60%; Δ 10.46% < -1%) |
| CFO/TA -0.12 > 3% & CFO -30.2m > Net Income -13.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (170.3m) vs 12m ago 11.46% < -2% |
| Gross Margin: 71.68% > 18% (prev 0.72%; Δ 7096 % > 0.5%) |
| Asset Turnover: 66.04% > 50% (prev 62.39%; Δ 3.65% > 0%) |
| Interest Coverage Ratio: -0.59 > 6 (EBITDA TTM -2.57m / Interest Expense TTM 8.33m) |
Altman Z'' -15.00
| A: 0.56 (Total Current Assets 229.4m - Total Current Liabilities 89.7m) / Total Assets 248.9m |
| B: -7.78 (Retained Earnings -1.94b / Total Assets 248.9m) |
| C: -0.02 (EBIT TTM -4.92m / Avg Total Assets 234.9m) |
| D: -8.27 (Book Value of Equity -1.94b / Total Liabilities 234.1m) |
| Altman-Z'' Score: -30.50 = D |
Beneish M -2.93
| DSRI: 1.07 (Receivables 81.0m/67.0m, Revenue 155.1m/137.7m) |
| GMI: 1.01 (GM 71.68% / 72.19%) |
| AQI: 0.78 (AQ_t 0.02 / AQ_t-1 0.03) |
| SGI: 1.13 (Revenue 155.1m / 137.7m) |
| TATA: 0.07 (NI -13.6m - CFO -30.2m) / TA 248.9m) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of HRTX shares?
Over the past week, the price has changed by -4.55%, over one month by +3.28%, over three months by +14.55% and over the past year by -29.61%.
Is HRTX a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HRTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.5 | 257.1% |
| Analysts Target Price | 4.5 | 257.1% |
| ValueRay Target Price | 1.1 | -10.3% |
HRTX Fundamental Data Overview February 03, 2026
P/B = 34.9859
P/EG = -0.18
Revenue TTM = 155.1m USD
EBIT TTM = -4.92m USD
EBITDA TTM = -2.57m USD
Long Term Debt = 139.7m USD (from longTermDebt, last quarter)
Short Term Debt = 780.0k USD (from shortTermDebt, last quarter)
Debt = 140.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 97.4m USD (from netDebt column, last quarter)
Enterprise Value = 327.0m USD (242.0m + Debt 140.4m - CCE 55.5m)
Interest Coverage Ratio = -0.59 (Ebit TTM -4.92m / Interest Expense TTM 8.33m)
EV/FCF = -10.50x (Enterprise Value 327.0m / FCF TTM -31.1m)
FCF Yield = -9.52% (FCF TTM -31.1m / Enterprise Value 327.0m)
FCF Margin = -20.08% (FCF TTM -31.1m / Revenue TTM 155.1m)
Net Margin = -8.75% (Net Income TTM -13.6m / Revenue TTM 155.1m)
Gross Margin = 71.68% ((Revenue TTM 155.1m - Cost of Revenue TTM 43.9m) / Revenue TTM)
Gross Margin QoQ = 59.74% (prev 73.50%)
Tobins Q-Ratio = 1.31 (Enterprise Value 327.0m / Total Assets 248.9m)
Interest Expense / Debt = 2.06% (Interest Expense 2.90m / Debt 140.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -3.89m (EBIT -4.92m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.56 (Total Current Assets 229.4m / Total Current Liabilities 89.7m)
Debt / Equity = 9.44 (Debt 140.4m / totalStockholderEquity, last quarter 14.9m)
Debt / EBITDA = -37.93 (negative EBITDA) (Net Debt 97.4m / EBITDA -2.57m)
Debt / FCF = -3.13 (negative FCF - burning cash) (Net Debt 97.4m / FCF TTM -31.1m)
Total Stockholder Equity = -18.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.78% (Net Income -13.6m / Total Assets 248.9m)
RoE = 72.92% (negative equity) (Net Income TTM -13.6m / Total Stockholder Equity -18.6m)
RoCE = -4.07% (EBIT -4.92m / Capital Employed (Equity -18.6m + L.T.Debt 139.7m))
RoIC = -2.67% (negative operating profit) (NOPAT -3.89m / Invested Capital 145.6m)
WACC = 6.46% (E(242.0m)/V(382.5m) * Re(9.26%) + D(140.4m)/V(382.5m) * Rd(2.06%) * (1-Tc(0.21)))
Discount Rate = 9.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.47%
Fair Price DCF = unknown (Cash Flow -31.1m)
EPS Correlation: 85.38 | EPS CAGR: 216.4% | SUE: 0.26 | # QB: 0
Revenue Correlation: 91.78 | Revenue CAGR: 17.83% | SUE: -0.32 | # QB: 0
EPS next Year (2026-12-31): EPS=-0.05 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+0.0% | Growth Revenue=+11.8%